Search Results
Aug 07, 2025, 16:03 ET BioLife Solutions Reports Second Quarter 2025 Financial Results
of convertible notes in Pluristyx, Inc. ("Pluristyx"), a Seattle-based developer of induced pluripotent stem cell ("iPSC") based products for cell therapy developers.The Company accounted for the PanTHERA transaction as an asset acquisition. Because the IRI
More news about: BioLife Solutions, Inc.
Aug 05, 2025, 12:49 ET Trailhead Biosystems erweitert sein Portfolio an iPSC-abgeleiteten Produkten um TrailBio®-hämatopoetische Vorläuferzellen
Markteinführung von TrailBio® Hämatopoetischen Vorläuferzellen bekannt. Diese Vorläuferzellen werden aus einer einzigen, gut charakterisierten iPSC-Linie unter Verwendung der proprietären High-Dimensional Design-of-Experiments (HD-DoE®)-Plattform von Trailhead gewonnen und bieten Forschern
More news about: Trailhead Biosystems Inc
Aug 05, 2025, 11:44 ET Cell Line and Membrane Market to Grow at 12.5% CAGR Through 2030
review of the induced pluripotent stem cell (iPSC) market. It analyzes the market by application areas such as drug development, academic research, and regenerative medicine, and by product functions such as cell culture and reprogramming. It also covers iPSC-derived cell types, including neurons, hepatocytes,
More news about: BCC Research LLC
Aug 05, 2025, 05:00 ET Trailhead Biosystems amplía su cartera de productos derivados de células madre pluripotentes inducidas (iPSC)
humanos escalables derivados de células madre pluripotentes inducidas (iPSC), anuncia el lanzamiento comercial de las células progenitoras hematopoyéticas TrailBio®. Estas células progenitoras se derivan de una única línea de iPSC bien caracterizada utilizando la plataforma patentada High-Dimensional
More news about: Trailhead Biosystems Inc
Aug 05, 2025, 05:00 ET Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells
This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® Hematopoietic Progenitor Cells join a growing portfolio of iPSC-derived human cell types designed to bridge the gap between discovery and
More news about: Trailhead Biosystems Inc
Aug 05, 2025, 05:00 ET Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells
This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® Hematopoietic Progenitor Cells join a growing portfolio of iPSC-derived human cell types designed to bridge the gap between discovery and
More news about: Trailhead Biosystems Inc
Aug 05, 2025, 05:00 ET Trailhead Biosystems élargit son portefeuille de cellules dérivées d'iPSC avec les cellules progénitrices hématopoïétiques TrailBio®
humains évolutifs dérivés de cellules souches pluripotentes induites (iPSC), annonce la commercialisation des cellules progénitrices hématopoïétiques TrailBio®. Ces cellules progénitrices sont dérivées d'une seule lignée iPSC bien caractérisée en utilisant la plateforme propriétaire High-Dimensional
More news about: Trailhead Biosystems Inc
Jul 28, 2025, 09:10 ET XellSmart Completed World's First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury
evaluating the safety of transplanted, iPSC-derived, spinal-cord neural progenitor cells and analyzing their potential therapeutic effects on patients with spinal cord injury (SCI). XellSmart is a leading biotechnology company dedicated to developing innovative iPSC-derived cell therapies. To date,
More news about: XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd.
Jul 28, 2025, 08:05 ET BioLife Solutions Makes Strategic Investment in Pluristyx
founding team at Pluristyx for many years, and have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency.
More news about: BioLife Solutions, Inc.
Jul 24, 2025, 08:00 ET Johnson & Johnson showcases latest advancements in Alzheimer's research at AAIC 2025
Microglial proteomic signature in human CSF allows stratification by APOE genotypes and is replicated in iPSC-based model July 28
More news about: Johnson & Johnson
Jul 23, 2025, 05:00 ET Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons
2025 /PRNewswire/ -- Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells at scale for drug discovery and cell therapy, introduces TrailBio® A9 Dopaminergic Neurons, a powerful new tool available
More news about: Trailhead Biosystems Inc
Jul 17, 2025, 11:00 ET BrainXell, Inc. Strengthens Executive Leadership with Paul Marcus and Dr. Su-Chun Zhang
Wis., July 17, 2025 /PRNewswire/ -- BrainXell, a leading producer of iPSC-derived human neurons and glia, is proud to announce the continued growth of its executive leadership team with the appointment of Paul
More news about: BrainXell, Inc.
Jul 10, 2025, 11:00 ET BrainXell, Inc. Appoints Katherine Vega Stultz as Chief Executive Officer and Board Director
July 10, 2025 /PRNewswire/ -- BrainXell, Inc., a leading biotechnology company developing iPSC-based CNS disease models and regenerative cell therapies, announces the appointment of Katherine Vega Stultz as its new
More news about: BrainXell, Inc.
Jul 10, 2025, 06:00 ET Vita Therapeutics and I Peace announced a development program to generate iPS-derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells
https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has agreed with Vita Therapeutics (Vita) to jointly develop universal iPS cells that will be used
More news about: I Peace, Inc.; VITA Theraputics
Jun 16, 2025, 10:40 ET HELP Therapeutics and China Resources Sanjiu Announce Strategic Partnership to Co-Develop and Commercialize HiCM-188 for Advanced Heart Failure in Mainland China
strategic partnership to co-develop and commercialize the investigational cell therapy HiCM-188 in Mainland China. HiCM-188 is the world's first iPSC-derived regenerative therapy for advanced heart failure to receive IND clearance in both China and the
More news about: HELP THERAPEUTICS
Jun 10, 2025, 07:30 ET Factor Bioscience to Unveil iMacrophages Engineered to Combat Solid Tumors at the ISSCR Annual Meeting
Hong Kong over the next few days." Details of the presentations are below: "Hypoimmune iPSC-derived Macrophages Engineered to Express IL-12 Activate Lymphocytes Against Platinum-Resistant Ovarian Cancer." -to be presented by Ian
More news about: Factor Bioscience Inc.
Jun 09, 2025, 08:07 ET Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting
efficacy of transplanted autologous iPSC-derived dopaminergic precursors in moderate to advanced Parkinson's Disease. Dr. Bratt-Leal's presentation will cover data for the first four patients of the ASPIRO Study*, a Phase 1/2a trial of the company's iPSC-derived autologous cell therapy (ANPD001).
More news about: Aspen Neuroscience, Inc.
Jun 09, 2025, 08:00 ET Neowise Biotechnology and BeOne Medicines Enter Licensing Agreement to Advance Development of Next-Generation Cell Therapies
terms of the agreement, Neowise will grant BeOne rights to one of its proprietary antigen-specific TCR molecules for the development of next-generation, iPSC-based off-the-shelf cell therapies. Under the terms of the agreement, Neowise will receive an upfront payment and will be eligible for future
More news about: Neowise Biotechnology